Change of operational policyThe 1067 clinical trial was financed by a third party and from earlier NR, I am sure it was stated that the clinical trial for 1326 would also be financed by a third party.
This statement from today’s NR comes as a nice surprise: “The clinical trial (for 1326) is fully financed, owned and controlled by Sirona.”
In my view, this sentence is the first really positive and potentially value-adding news in years.
Thus, there will be no third party right of first refusal. If results are favourable, it gives Sirona an opportunity to let multiple third parties compete in the bidding for the compound. With the assistance of Linda Pullan, I think Sirona will be able to succeed with that kind of bidding activity.
I am not selling any shares at this point of time.